Abstract
Patients with diffuse large B-cell lymphoma (DLBCL) and positive bone marrow biopsy at diagnosis are reported to have inferior outcomes and higher risk for central nervous system (CNS) relapse after combination chemotherapy compared with marrow-negative patients (Blood 2007; 110:1278 and Blood 1998; 91:1178). To determine whether treatment with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) affects this association, investigators in British Columbia and New Zealand conducted a retrospective, population-based study of 795 patients with de novo DLBCL. The objective was to …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
